Panagora Asset Management Inc Chinook Therapeutics, Inc. Transaction History

Panagora Asset Management Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$18.63 - $27.35 $128,919 - $189,262	-6,920 Reduced 21.53%	25,220 $660,000
Q3 2022 Nov 14, 2022	BUY	$17.51 - $23.37 $562,771 - $751,111	32,140 New	32,140 $632,000
Q2 2021 Aug 11, 2021	SELL	$13.6 - $18.98 $421,396 - $588,095	-30,985 Closed	0 $0
Q1 2021 May 12, 2021	SELL	$14.17 - $19.11 $376,298 - $507,485	-26,556 Reduced 46.15%	30,985 $482,000
Q4 2020 Feb 10, 2021	SELL	$11.9 - $20.91 $2.89 Million - $5.07 Million	-242,538 Reduced 80.82%	57,541 $912,000
Q3 2020 Nov 13, 2020	BUY	$11.4 - $15.5 $3.42 Million - $4.65 Million	300,079 New	300,079 $729,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Panagora Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Panagora Asset Management Inc with notifications on news.